NNHHF - NHS Industries and Cannabis Science Announce Termination of Joint Venture Agreement Previously Announced on August 28 2019

VANCOUVER, BC / ACCESSWIRE / September 27, 2019 / NHS Industries, Ltd. ("NHS Industries" or the "Company") (CSE:NHS)(OTC:NNHHF) and Cannabis Science, Inc. ("Cannabis Science")(OTC:CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, have mutually agreed to terminate the previously announced Joint Venture Agreement of August 28, 2019. During further review of numerous proposed logistics, both parties, NHS and Cannabis Science, agreed that anticipated synergies that would create a mutually beneficial environment to further the joint venture were not present.

About NHS Industries Ltd.

NHS owns 5.5 acres of prime agricultural land in Langley, BC that includes over 48,000 square feet of greenhouse capacity. NHS common shares are listed on the Canadian Securities Exchange. For further information about NHS, please consult the Company's profile on SEDAR at www.sedar.com.

###

On Behalf of the Board of Directors of NHS Industries Ltd.

Carman Parente
President and Chief Executive Officer
info@nhsindustries.ca
1-888- 346-5153

NHS Industries Ltd. Forward Looking Statements

This news release contains forward-looking statements, which relate to future events or future performance and reflect management's current expectations and assumptions. Such forward-looking statements reflect management's current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, but not limited to completion of planned improvements on schedule and on budget, the availability of financing needed to complete the Company's planned improvements on commercially reasonable terms, delays in obtaining statutory and/or regulatory approval for production plans, the ability to mitigate the risk of loss through appropriate insurance policies, among others. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation. This news release does not constitute an offer to sell securities and the Company is not soliciting an offer to buy securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

This news release does not constitute an offer of securities for sale in the United States. These securities have not and will not be registered under United States Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States or to a U.S. Person unless so registered, or an exemption from registration is relied upon.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.

SOURCE: NHS Industries, Ltd.